S&P Futures
6,009.75 +22.75 (+0.38%) Dow Futures
44,621.00 +226.00 (+0.51%) Nasdaq Futures
20,943.00 +93.25 (+0.45%) Russell 2000 Futures
2,445.60 +32.00 (+1.33%) Crude Oil
71.28 +0.04 (+0.06%) Gold
2,715.90 +3.70 (+0.14%)
Avenue Therapeutics, Inc. (ATXI)
Avenue Therapeutics, Inc.
1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
781 652 4500
https://www.avenuetx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 3
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Alexandra MacLean M.D. | CEO & Director | 413.2k | N/A | 1967 |
| Mr. David Jin | Interim CFO, COO & Corporate Secretary | N/A | N/A | 1990 |
| Dr. Lindsay Allan Rosenwald | Executive Director | N/A | N/A | 1955 |
| Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer | 69.12k | N/A | 1947 |
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Corporate Governance
Avenue Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
